Nasus Pharma
Quarterly Financials
| Values in thousands | 2026-06-30 | 2025-12-31 |
|---|---|---|
EBITDA | -5,948 | -1,235 |
Net Income | -5,942 | -1,391 |
Free Cash Flow | -1,989 | -1,370 |
Cash | 7,818 | 1,237 |
Basic Shares | 11,070 | 9,015 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -4,904 | -1,523 | -956 | -2,134 |
EBIT | -4,904 | -1,078 | -1,147 | -2,134 |
Net Income | -5,856 | -1,532 | -1,051 | -1,711 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -4,932 | -665 | -1,029 | -1,211 |
Cash | 1,237 | 284 | 193 | 154 |
Basic Shares | 8,010 | 9,059 | 9,059 | 9,059 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.54 |
2025-12-31 | $0 |
2025-09-30 | -$0.14 |
2025-06-30 | -$0.09 |